ClinicalTrials.gg
Active, not recruitingNCT03772834Updated Nov 4, 2026

Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer

A Phase 2/3 interventional study of Exercise Intervention and Methylphenidate in Prostate Carcinoma, sponsored by M.D. Anderson Cancer Center. Active, not recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by M.D. Anderson Cancer Center · Phase 2/3, Interventional, and Supportive care

How we know

Updated Nov 4, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 124 studies in Prostatic Neoplasms by M.D. Anderson Cancer Center — 22 open to participants now, 40 under way, 3 of them phase 3. Prostatic Neoplasms · M.D. Anderson Cancer Center.

Planned enrollment
10th of 106
200 · median 41
Started
2019
with 8 others
Phase 2/3
Only one
of the 124
Primary completion
2028-11
later than 33 of 39 live
Registered
83rd of 124
by date

Among the 124 studies in Prostatic Neoplasms by M.D. Anderson Cancer Center, this one is the 10th largest by planned enrollment of the 106 interventional ones that give a count, is one of 9 that started in 2019, is the only one in phase 2/3, reaches primary completion later than 33 of the 39 other live ones, and was the 83rd registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

22 of the 124 studies in Prostatic Neoplasms by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 124 studies in Prostatic Neoplasms by M.D. Anderson Cancer Center, or all of them as a file.
02

Study summary

This phase II/III trial studies how well methylphenidate and exercise work in reducing cancer-related fatigue in patients with prostate cancer. Methylphenidate is a type of central nervous system stimulant that can improve cognitive ability, mainly in memory and cognitive function. Exercise can improve mood and the physical aspects of cancer-related fatigue. Giving methylphenidate in combination with exercise may work better in reducing cancer-related fatigue in patients with prostate cancer.

Read the detailed description

PRIMARY OBJECTIVE:

I. To determine if the combination of exercise (EX) plus methylphenidate (MP) is superior to exercise plus placebo in the treatment of cancer-related fatigue (CRF) in patients with prostate cancer scheduled to receive radiotherapy with androgen deprivation therapy for 12 weeks.

SECONDARY OBJECTIVE:

I. To determine the effects of combined exercise plus methylphenidate on quality-of-life, mood, physical, and cognitive measures.

EXPLORATORY OBJECTIVES:

I. To identify potential synergistic effects of exercise and methylphenidate in improvement of CRF.

II. To explore changes in brain activity by electroencephalography (EEG) in responders (with 4 point or greater change in Functional Assessment of Chronic Illness Therapy-Fatigue [FACIT-F] scores) versus (vs) non-responders to the intervention.

OUTLINE: Patients are randomized to 1 of 4 groups.

GROUP I: Patients receive methylphenidate orally (PO) twice daily (BID) and undergo exercise program consisting of resistance training twice weekly (BIW) and walking 15- 40 minutes a day 4 days a week for 12 weeks.

GROUP II: Patients receive a placebo PO BID and undergo exercise program consisting of resistance training BIW and walking 15-40 minutes a day for 4 days a week for 12 weeks.

GROUP III: Patients receive methylphenidate PO BID and undergo stretching for 4 days a week for 12 weeks.

GROUP IV: Patients receive a placebo PO BID and undergo stretching for 4 days a week for 12 weeks.

After completion of study treatment, patients are followed up at 3 months.

03

Conditions studied

  • Prostate Carcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of prostate cancer and be scheduled to receive radiotherapy with concurrent androgen deprivation therapy, and presence of fatigue with severity of 1/10, on a 0-10 scale for at least 2 weeks
  • Patient not regularly engaging in moderate aerobic exercise for >90 minutes/week and/or vigorous aerobic exercise for >30 minutes/week, and/ or strength training for >/= 1 day/week
  • Have no clinical evidence of cognitive failure as evidenced by Memorial Delirium Assessment Scale score of \</=13 at baseline
  • Be aged 18 years or older
  • Be willing to engage in follow-up telephone calls with a research staff
  • Be willing to participate in the exercise programs
  • Have telephone access so they can be contacted by the research staff
  • Have a level of >/= 10 g/dL within 2 weeks of enrollment
  • Be able to understand the description of the study and give written
  • Have a Zubrod performance status score of 0 to 2
  • Seen at an outpatient clinic at MD Anderson Cancer Center, its Houston Area Locations (HALs) or Smith Radiation Oncology Clinic (HHS)

Exclusion criteria

Exclusion Criteria:

  • Have a major to MethylphenidateMP) (e.g., allergy/ to study medications or their constituents), exercise (e.g., cardiac disease), or conditions making adherence difficult as determined by the attending physician
  • Be currently taking MP, or have taken it within the previous 10 days
  • Be unable to complete the baseline assessment forms (e.g., due to language or sensory barriers) or to understand the recommendations for participation in the study
  • Need monoamine oxidase inhibitors, tricyclic antidepressants, or clonidine
  • Have glaucoma
  • Have severe cardiac disease ( functional class III or IV)
  • Have tachycardia and/or uncontrolled hypertension
  • Be currently receiving anticoagulants, anticonvulsants (phenobarbital, diphenylhydantone, primidone), phenylbutazone, and/or tricyclic drugs (imipramine, clomipramine, or desipramine).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Group I (methylphenidate, resistance training, walking)

    Patients receive methylphenidate PO BID and undergo exercise program consisting of resistance training BIW and walking 15- 40 minutes a day 4 days a week for 12 weeks.

    Behavioral: Exercise Intervention · Drug: Methylphenidate · Other: Quality-of-Life Assessment · Other: Questionnaire Administration

  • Active comparator
    Group II (placebo, resistance training, stretching)

    Patients receive a placebo PO BID and undergo exercise program consisting of resistance training BIW and walking 15-40 minutes a day for 4 days a week for 12 weeks.

    Behavioral: Exercise Intervention · Other: Placebo · Other: Quality-of-Life Assessment · Other: Questionnaire Administration

  • Active comparator
    Group III (methylphenidate, stretching)

    Patients receive methylphenidate PO BID and undergo stretching for 4 days a week for 12 weeks.

    Drug: Methylphenidate · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Other: Stretching

  • Active comparator
    Group IV (placebo, stretching)

    Patients receive a placebo PO BID and undergo stretching for 4 days a week for 12 weeks.

    Other: Placebo · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Other: Stretching

Interventions

  • BehavioralExercise Intervention

    Undergo resistance training and walking

  • Given PO

    Also known as: Daytrana

  • OtherPlacebo

    Given PO

    Also known as: placebo therapy, PLCB, sham therapy

  • OtherQuality-of-Life Assessment

    Ancillary studies

    Also known as: Quality of Life Assessment

  • OtherQuestionnaire Administration

    Ancillary studies

  • OtherStretching

    Undergo stretching

06

What researchers measure

Primary outcomes

  1. Level of cancer-related fatigue in all groups

    Will measure cancer-related fatigue (CRF) using the area under the curve (AUC) of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) subscale score. The intervention exposure will be operationalized as proportion of the total minutes of prescribed exercise intervention the study patient was actually able to participate, or the proportion of prescribed study medication the study patient was able to actually take.

    Time frame: Up to 12 weeks

Secondary outcomes

  1. Change in quality of life, mood, physical and cognitive measures in all groups

    Will use a mixed-effects model to compare changes in Functional Assessment of Cancer Therapy - General (FACT-G), Pittsburgh Sleep Quality Index (PSQI), Multidimensional Fatigue Symptom Inventory - Short Form (MFSI-SF), Hospital Anxiety and Depression Scale (HADS), usual gait speed, hand grip strength (HGS), 30 second chair stand test (30s-CST), actigraphy, VO2 max, and C-reactive protein scores over time between the four treatment groups. For the mixed effects model, we will estimate the slopes for the changes in scores over time for each group and test the difference in these slopes.

    Time frame: Baseline up to 12 weeks

Other outcomes

  1. Synergistic effects of methylphenidate and exercise in all groups

    Will measure the synergistic effects of methylphenidate and exercise in improving CRF using the AUC of the FACIT-F subscale score. The analysis will be conducted using a linear model with the AUC as the response variable and indicator variables for the exercise and methylphenidate main effects as well as a product term of these indicator variables to assess the magnitude of synergy.

    Time frame: Up to 12 weeks

  2. Change in brain activity by electroencephalography (EEG) in responders versus non-responders as measured by the FACIT-F score

    Responders are identified as those who report a 4 point or greater change, while non-responders report less than a 4 point change in the FACIT-F score. EEG data will be grouped according to response status. Between-group differences will be examined using univariate analysis of variance (ANOVA) with condition (responders or non-responders) as the fixed factor of interest, and the change of power from baseline to the resting state EEG at day 29 and day 84 as the dependent variable. Additional analyses will include analysis of covariance (ANCOVA) by adjusting for baseline covariates including age, stage of disease, total dose of radiotherapy, and other covariates as necessary.

    Time frame: Baseline up to 12 weeks

07

Study locations

1 site
08

References and documents

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2019 (actual). Primary completion is estimated for Nov 2028, 116 months after the start.

Of 43 phase 2/3 interventional studies under Prostatic Neoplasms, half reached primary completion within 115 months of starting (the median), counting those still running; a quarter within 32. This study's planned 116 months is close to that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Nov 2026 → Nov 2028 and completion Nov 2026 → Nov 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2018
First posted
Dec 11, 2018
StartActual
Mar 25, 2019
Primary completionEst.
Nov 30, 2028was Nov 2026
CompletionEst.
Nov 30, 2028was Nov 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 30, 2026→Nov 30, 2028
Nov 4, 2026
Study completion
Nov 30, 2026→Nov 30, 2028
Nov 4, 2026
Show all 2 updates
  1. Nov 4, 2026
    Primary completion Nov 30, 2026→Nov 30, 2028
    Study completion Nov 30, 2026→Nov 30, 2028
    + 1 other change: verification date
  2. Oct 7, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03772834
Responsible party
Sponsor
First posted
Dec 11, 2018
Start date
Mar 25, 2019
Primary completion
Nov 30, 2028 (estimated)
Completion
Nov 30, 2028 (estimated)
Last update
Nov 4, 2026

Study contacts

Sriram Yennu, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methylphenidate

Start the discussion